ALX Oncology Holdings Inc.ALXONASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank48
5Y CAGR-26.9%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-26.9%/yr
Long-term compound
Percentile
P48
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.60% |
| Q3 2025 | -6.60% |
| Q2 2025 | -31.28% |
| Q1 2025 | 12.02% |
| Q4 2024 | 16.16% |
| Q3 2024 | -8.36% |
| Q2 2024 | 14.08% |
| Q1 2024 | -6.54% |
| Q4 2023 | -16.91% |
| Q3 2023 | 2.93% |
| Q2 2023 | -1.95% |
| Q1 2023 | 12.57% |
| Q4 2022 | -9.45% |
| Q3 2022 | 3.66% |
| Q2 2022 | -8.25% |
| Q1 2022 | 1.27% |
| Q4 2021 | 19.11% |
| Q3 2021 | 25.09% |
| Q2 2021 | 16.68% |
| Q1 2021 | -23.30% |
| Q4 2020 | 26.82% |
| Q3 2020 | 41.27% |
| Q2 2020 | 115.34% |
| Q1 2020 | 32.94% |
| Q4 2019 | 18.12% |
| Q3 2019 | 38.14% |
| Q2 2019 | 15.48% |
| Q1 2019 | 0.00% |